SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Visara Doses First Patient in Phase 2b Wet AMD Trial

Visara says its ASCEND trial is evaluating VIS-101 for sustained disease control in wet AMD.

NBP

Story updates

12:02:06 PM UTC
SquawkNews
Head-to-head trial designed to evaluate VIS-101’s potential for sustained disease control with extended treatment intervalsPhase 2a results showed approximately 50% of patients in the 6 mg treatment-naïve cohort remained retreatment-free six months after the last loading doseROCKVILLE, Md., Nov. 18…

Related stories